FDA, weighing Perrigo's OTC birth control application, raises questions about real-world use

As a long-awaited advisory committee meeting on Perrigo’s over-the-counter birth control prospect Opill nears, the FDA says many big questions remain. Chief among them: Will people use the drug as intended in the real world?